![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » AstraZeneca Begins Human Trials of COVID-19 Monoclonal Antibody
AstraZeneca Begins Human Trials of COVID-19 Monoclonal Antibody
![AstraZeneca](https://www.fdanews.com/ext/resources/test/Device_Images2/AstraZeneca.gif?t=1576126438&width=430)
August 26, 2020
AstraZeneca dosed its first participants in a phase 1 trial of its investigational monoclonal antibody product AZD7442 for preventing and treating COVID-19.
The trial will evaluate the safety, tolerability and pharmacokinetics of the treatment in up to 48 healthy participants ages 18 to 55 years old in the United Kingdom.
AZD7442 is a combination of two monoclonal antibodies that were discovered by researchers at Vanderbilt University Medical Center and licensed to AstraZeneca in June.
Upcoming Events
-
21Oct